Aitiabio( Formerly GNS Healthcare)

Aitia, derived from the Greek word for causality, is at the forefront of revolutionizing drug discovery by leveraging advanced technologies. The company specializes in creating Digital Twins of human diseases using multi-omic patient data and causal AI. This innovative approach allows Aitia to simulate the efficacy and safety of drugs at the individual patient level, thereby improving patient outcomes and accelerating the development of breakthrough drugs. Aitia primarily serves pharmaceutical companies and research institutions, operating in the biotechnology and healthcare markets. The business model is centered around providing cutting-edge solutions that integrate high-performance computing and causal learning to uncover the hidden biological mechanisms driving disease outcomes. Revenue is generated through partnerships, licensing agreements, and service contracts with its clients.

Keywords: Digital Twins, causal AI, multi-omic data, drug discovery, patient outcomes, biotechnology, healthcare, high-performance computing, simulation technology, pharmaceutical partnerships.